Results 131 to 140 of about 3,454 (177)

Dislocation of Dexamethasone Intravitreous Implant

Archives of Ophthalmology, 2012
tiviral drugs. Eur J Ophthalmol. 2001;11(2):200-202. 22. Yang CM, Wang WW, Lin CP. Progressive outer retinal necrosis syndrome as an early manifestation of human immunodeficiency virus infection. J Formos Med Assoc. 1999;98(2):141-144. 23. Perez-Blazquez E, Traspas R, Mendez Marin I, Montero M.
Voykov, Bogomil Nikolov, Bartz-Schmidt, Karl U.   +1 more
openaire   +3 more sources

Dexamethasone intravitreal implant in serpiginous choroiditis

British Journal of Ophthalmology, 2016
To assess the efficacy and safety of dexamethasone (DEX) intravitreal implant in patients with active serpiginous choroiditis (SC) already receiving maximal tolerated systemic immunosuppressive therapy.In this retrospective longitudinal study we evaluated patients receiving 0.7 mg DEX intravitreal implant for active SC despite maximal systemic ...
Miserocchi, Elisabetta, Berchicci, Luigi, Iuliano, Lorenzo, Modorati, Giulio, Bandello, Francesco   +4 more
openaire   +2 more sources

INTRAVITREAL DEXAMETHASONE IMPLANTATION FOR BIRDSHOT CHORIORETINOPATHY

RETINAL Cases & Brief Reports, 2017
Purpose: Birdshot chorioretinopathy is a rare form of posterior uveitis. This article reports a case series of patients with HLA-A29+ birdshot chorioretinopathy managed with intravitreal dexamethasone implants.
James, Walsh, Ashvini K, Reddy
openaire   +2 more sources

Dexamethasone Intravitreal Implant (Ozurdex)

Canadian Journal of Health Technologies, 2023
CADTH recommends that Ozurdex not be reimbursed by public drug plans for the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic and have had an inadequate response to prior anti–vascular endothelial growth factor (VEGF) therapy. Evidence from 1 clinical trial and 2 observational studies was insufficient to demonstrate
openaire   +1 more source

Safety of 6000 intravitreal dexamethasone implants

British Journal of Ophthalmology, 2019
PurposeTo evaluate the real-life safety profile of intravitreal dexamethasone implant injection for various retinal conditions.MethodsRetrospective multicenter analysis of intravitreal dexamethasone implant injections (700 µg) due to various retinal conditions including central retinal venous occlusion (1861 injections), diabetic macular oedema (3104 ...
Masarwa, Dua, Novais, Eduardo, Giancipoli, Ermete, Cagini, Carlo, Bandello, Francesco, Dolz Marco, Rosa, Kumar, S., Sarvaiya, Chintan, Veritti, Daniele, Sarvaiya, Chintan, Veritti, Daniele, Zur, Dinah, Masarwa, Dua, Zur, Dinah, Patyal, S., Kumar, S., Masarwa, Dua, Zur, Dinah, Veritti, Daniele, Sarvaiya, Chintan, Bernal-Morales, Carolina, Cebeci, Zafer, Chaikitmongkol, Voraporn, Sarao, Valentina, Sharma, V., Singh, Sumit Randhir, Cohen, Shai, Fraser-Bell, Samantha, Patyal, S., Kumar, S., Dolz Marco, Rosa, Gallego-Pinazo, Roberto, Shenoy, Prateek, Gabrielle, Pierre-Henry, D'Anna-Mardero, Oriana, Rajesh, Bindu, Rassu, Nicolo, Asencio-Duran, Monica, Maia, Mauricio, Cavalleri, Michele, Rasheed, Mohammed Abdul, Nagpal, Manish, Casella, Marcelo, Lupidi, Marco, Avila, Marcos, Berrocal, Maria, Cavalleri, Michele, Maia, Mauricio, Iglicki, Matias, Berrocal, Maria, Avila, Marcos, Iglicki, Matias, Lupidi, Marco, Casella, Marcelo, Rasheed, Mohammed Abdul, Asencio-Duran, Monica, Rassu, Nicolo, Ayhan, Ziya, Cebeci, Zafer, Al-khersan, Hasenin, Wong, J. S., Chaikitmongkol, Voraporn, Nagpal, Manish, Okada, Mali, Wu, Lihteh, Raji, K., Sarao, Valentina, Sharma, V., Singh, Sumit Randhir, Cohen, Shai, Fraser-Bell, Samantha, Patyal, S., Novais, Eduardo, Giancipoli, Ermete, Raji, K., Wu, Lihteh, Okada, Mali, Bandello, Francesco, D'Anna-Mardero, Oriana, Gabrielle, Pierre-Henry, Shenoy, Prateek, Gallego-Pinazo, Roberto, Wong, J. S., Al-Khersan, Hasenin, Sharma, Ashish, Sala-Puigdollers, Anna, Maiti, Aniruddha, Maia, Andre, AYHAN, ZİYA, SAATCİ, ALİ OSMAN, Dolz Marco, Rosa, Gallego-Pinazo, Roberto, Shenoy, Prateek, Gabrielle, Pierre-Henry, D'Anna-Mardero, Oriana, Marashi, Ameen, Rassu, Nicolo, Asencio-Duran, Monica, Rasheed, Mohammed Abdul, Cavalleri, Michele, Maia, Mauricio, Iglicki, Matias, Berrocal, Maria, Avila, Marcos, Lupidi, Marco, Casella, Marcelo, Nagpal, Manish, Bernal-Morales, Carolina, Sen, Alok C., Banker, Alay, Mansour, Ahmad, Goud, Abhilash, Singh, A., Gupta, A., Chhablani, Jay, Kodjikian, Laurent, Arevalo, J. Fernando, Lanzetta, Paolo, Okada, Mali, Farah, Michel Eid, Querques, Giuseppe, Udaondo Mirete, Patricia, Mishra, Sanjay Kumar, Wu, Lihteh, Sarao, Valentina, Rodriguez-Valdes, Patricio J., Sahoo, Niroj Kumar, Busch, Catharina, Fung, Adrian T., Zarranz-Ventura, Javier, Raji, K., Wong, J. S., Al-khersan, Hasenin, Bandello, Francesco, Giancipoli, Ermete, Novais, Eduardo, Bernal-Morales, Carolina, Ayhan, Ziya, Cebeci, Zafer, Chaikitmongkol, Voraporn, Sarao, Valentina, Sharma, V., Singh, Sumit Randhir, Cohen, Shai, Fraser-Bell, Samantha   +144 more
openaire   +7 more sources

PERSISTENT REMNANTS OF DEXAMETHASONE INTRAVITREAL IMPLANT (OZURDEX)

Retina, 2020
Purpose: To describe persistent remnants of dexamethasone intravitreal implant (DEX implant) and evaluate the risk factors for remnant persistence in patients who received a DEX implant. Methods: This retrospective observational study involved a retrospective chart review of 133 ...
Jee Taek, Kim, Seok Hyun, Lee, Sang Uk, Choi   +2 more
openaire   +2 more sources

Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant

Investigative Ophthalmology and Visual Science, 2011
To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.).Thirty-four male monkeys (Macaca fascicularis) received bilateral 0.7-mg DEX implants. Blood, vitreous humor, and retina samples were collected at predetermined intervals up to 270 days after administration ...
Scott M Whitcup, Michael R Robinson, Baruch D Kuppermann   +2 more
exaly   +3 more sources

MIGRATION OF INTRAVITREAL DEXAMETHASONE IMPLANT TO ANTERIOR CHAMBER

RETINAL Cases & Brief Reports, 2013
Purpose: To describe two cases of migration of intravitreally injected dexamethasone implant into the anterior chamber. Methods: Charts were reviewed of two patients who received sustained-release dexamethasone implant intravitreally for chronic intractable cystoid macular edema.
Vamsi K, Gullapalli, David A, DiLoreto
openaire   +2 more sources

Intravitreal dexamethasone implants for non‐infectious uveitis

Clinical & Experimental Ophthalmology, 2019
AbstractImportanceInflammatory‐mediated cystoid macular oedema (CMO) is the most common inflammatory‐mediated threat to vision in non‐infectious uveitis (NIU). Corticosteroid therapy is the cornerstone to the management of CMO in NIU. Sustained‐release dexamethasone (DEX) implant devices provide localized therapy.BackgroundThe authors present a series ...
Matthew McCartney, Peter McCluskey, Sophia Zagora   +2 more
openaire   +2 more sources

Cytomegalovirus Retinitis Associated With Intravitreal Dexamethasone Implant Injection

Journal of VitreoRetinal Diseases, 2023
Purpose: To describe an immunocompetent patient with cytomegalovirus (CMV) retinitis after dexamethasone implant injection and review previously documented cases. Methods: A review of case reports and literature was performed. Results: A 75-year-old man presented with acute decreased vision in the left eye.
Marissa K, Shoji, Jesse D, Sengillo, Akaanksh, Shetty, Joshua, Uhr, Jayanth, Sridhar   +4 more
openaire   +2 more sources